BRUSSELS -
- CE Markings for Additional New Indications Further Validate Use of Abbott’s Drug Eluting Stents in Treating a Range of High-Risk and Complex Patients
Abbott (NYSE: ABT) today announced that both the XIENCE PRIME(TM) Everolimus Eluting Coronary Stent System(1) and the XIENCE V(R) Everolimus Eluting Coronary Stent System have received additional new CE Markings (Conformite Europeenne) covering the treatment of patients with diabetes. Receiving these new indications among the European Union Member States validates the use of XIENCE PRIME and XIENCE V to treat patients with diabetes. Coronary artery disease is one of the most common cardiovascular complications of diabetes and is the number one cause of death among European adults with diabetes(2).
“This expanded indication further confirms XIENCE PRIME and XIENCE V as important options for physicians who are treating patients with diabetes,” said Charles Simonton, M.D., FACC, FSCAI, divisional vice president, Medical Affairs, and chief medical officer, Abbott Vascular. “Patients with diabetes tend to be sicker and have more challenging anatomy, such as small vessels or long lesions, which can be difficult to treat. The deliverability of both devices provides physicians with confidence to easily reach the lesion site.”
In addition to diabetes, XIENCE PRIME and XIENCE V also received CE Mark for expanded indications to treat patients that have complex disease, including dual vessels, small vessels and jailed side branches (small side branches of less than 2.0 mm in diameter that are covered, or “jailed,” when a larger artery is stented).
The expanded indications for XIENCE PRIME and XIENCE V are based on randomized clinical trial data from the SPIRIT family of trials that support the safety and performance of the stents in these patient subgroups. XIENCE PRIME also is indicated for use in long vessels and is available in stent lengths of 33 mm and 38 mm. Both XIENCE PRIME and XIENCE V leverage the excellent outcomes from the extensive body of clinical evidence from the SPIRIT family of clinical trials. Most recently, data from the company’s SPIRIT IV trial comparing XIENCE V to the TAXUS(R) Express2(TM) Paclitaxel-Eluting Coronary Stent System were presented at the Transcatheter Cardiovascular Therapeutics (TCT) annual meeting in September 2009. With 3,690 patients, the SPIRIT IV trial is one of the largest head-to-head randomized clinical trials between two drug eluting stents and includes more than 1,100 patients with diabetes.
XIENCE PRIME and XIENCE V are based upon the well-tested design utilized in the MULTI-LINK VISION(R) family of stents, which is the most widely used stent platform in the world - more than 2 million of Abbott’s cobalt chromium stents have been implanted worldwide.
XIENCE PRIME received CE Mark in June 2009, and XIENCE V received CE Mark in 2006. XIENCE PRIME is an investigational device in the United States and is not available for sale in the United States or outside of jurisdictions in which the product has been CE Marked. These additional indications apply to XIENCE V exclusively in countries where the product bears a CE Mark.
About Diabetes and Cardiovascular Disease
The high blood glucose levels associated with diabetes can lead to increased deposits of fatty materials on the insides of the blood vessel walls. These deposits may affect blood flow to the heart, increasing the chance of clogging and hardening of blood vessels. Patients with diabetes who also have coronary artery disease often have poorer outcomes after stent procedures because their blood vessels tend to build up more plaque than the vessels of non-diabetic patients, and their coronary artery disease advances more quickly.
About XIENCE PRIME and XIENCE V
XIENCE PRIME is the latest innovation from Abbott’s robust vascular research program and is commercially available in CE Mark countries. XIENCE PRIME offers a novel stent design and a delivery system designed for greater flexibility and enhanced deliverability. XIENCE PRIME is available in a broad size matrix, including XIENCE PRIME SV for small vessels and XIENCE PRIME LL for long lesions.
Abbott’s market-leading XIENCE V drug eluting stent is commercially available in the United States, Europe and other international markets. XIENCE V is an investigational device in Japan and is currently under review by Japan’s Ministry of Health, Labour and Welfare and the Pharmaceuticals and Medical Devices Agency.
Abbott also supplies a private-label version of XIENCE V to Boston Scientific called the PROMUS(R) Everolimus-Eluting Coronary Stent System. PROMUS is designed and manufactured by Abbott and supplied to Boston Scientific as part of a distribution agreement between the two companies.
Everolimus, developed by Novartis Pharma AG, is a proliferation signal inhibitor, or mTOR inhibitor, licensed to Abbott by Novartis for use on its drug eluting stents. Everolimus has been shown to inhibit in-stent neointimal growth in the coronary vessels following stent implantation, due to its anti-proliferative properties.
XIENCE V is indicated for improving coronary luminal diameter in patients with symptomatic heart disease due to de novo native coronary artery lesions (lesions less than or equal to 28 mm) with reference vessel diameters of 2.5 mm to 4.25 mm. Additional information about XIENCE PRIME and XIENCE V, including important safety information, is available online at www.xienceprime.com, www.xiencev.com or www.abbottvascular.com/en_US/content/document/eIFU_XienceV.pdf.
About Abbott Vascular
Abbott Vascular, a division of Abbott, is one of the world’s leading vascular care businesses. Abbott Vascular is uniquely focused on advancing the treatment of vascular disease and improving patient care by combining the latest medical device innovations with world-class pharmaceuticals, investing in research and development, and advancing medicine through training and education. Headquartered in Northern California, Abbott Vascular offers a comprehensive portfolio of vessel closure, endovascular and coronary products.
About Abbott
Abbott is a global, broad-based health care company devoted to the discovery, development, manufacture and marketing of pharmaceuticals and medical products, including nutritionals, devices and diagnostics. The company employs more than 72,000 people and markets its products in more than 130 countries.
Abbott’s news releases and other information are available on the company’s Web site at www.abbott.com.
(1) XIENCE PRIME is an investigational device in the United States and is not available for sale.
(2) Ryden L, Standl E, Bartnik M, et al. Guidelines on diabetes, pre-diabetes, and cardiovascular diseases: executive summary: The Task Force on Diabetes and Cardiovascular Diseases of the European Society of Cardiology (ESC) and of the European Association for the Study of Diabetes (EASD). Eur Heart J 2007;28(1):88-136
Source: Abbott
Media, Jonathon Hamilton, +1-408-845-3491, Jennie Kim, +1-408-845-1755, Financial, John Thomas, +1-847-938-2655, Tina Ventura, +1-847-935-9390, all of Abbott
Related Press Releases
Abbott's XIENCE V(R) Demonstrates Significantly Lower Rates of MACE and Stent Thrombosis Compared to TAXUS(R) Liberte in Investigator-Initiated COMPARE TrialSeptember 22nd, 2009 SAN FRANCISCO -
- Independent Study of 1,800 Patients Affirms Outstanding Performance of XIENCE V vs. TAXUS Liberte
Late-breaking data presented today from the COMPARE trial demonstrated that Abbott's (NYSE: ABT) market-leading XIENCE V(R) Everolimus Eluting Coronary Stent System demonstrated significantly better outcomes in key safety and efficacy measures compared to the TAXUS(R) Liberte Paclitaxel-Eluting Coronary Stent System (TAXUS).
Abbott's XIENCE V(R) Superior to TAXUS(R) in Key Safety and Efficacy Measures in SPIRIT IV TrialSeptember 22nd, 2009 SAN FRANCISCO -
At One Year, XIENCE V Demonstrates:
- Statistical Superiority on Primary Endpoint of Target Lesion Failure, with a 38 Percent Reduction Compared to TAXUS
- 74 Percent Reduction in Stent Thrombosis (Blood Clots) Compared to TAXUS
- Low Event Rates across Multiple Subgroups of Complex Patients
Late-breaking data from the SPIRIT IV trial demonstrated that Abbott's market-leading XIENCE V(R) Everolimus Eluting Coronary Stent System achieved superiority in the key safety and efficacy measures of target lesion failure (TLF) and target lesion revascularization (TLR) compared to the TAXUS(R) Express2(TM) Paclitaxel-Eluting Coronary Stent System (TAXUS) at one year. With 3,690 patients, the SPIRIT IV trial is one of the largest randomized clinical trials between two drug eluting stents.
Abbott's XIENCE V(R) Continues to Outperform TAXUS With Sustained Clinical Advantages and Impressive Long-Term Safety Results in SPIRIT III TrialSeptember 20th, 2009 SAN FRANCISCO -
- Market-Leading XIENCE V Demonstrates Single-Digit Rate of Major Adverse Cardiac Events (MACE) at Three Years and a 43 Percent Reduction vs. TAXUS
- No Additional Stent Thrombosis between Two and Three Years, and Impressive Low Rate of Very Late Stent Thrombosis for XIENCE V
Long-term data presented today from the SPIRIT III pivotal U.S.
Abbott Launches Next-Generation XIENCE PRIME(TM) Drug Eluting Stent in International MarketsAugust 30th, 2009 BARCELONA, Spain -
- New Cobalt Chromium Stent Offers Enhanced Deliverability with a Broad Matrix of Sizes
- Built Upon the Proven Track Record of Superior Clinical Outcomes of Abbott's Market-Leading XIENCE V(R) Drug Eluting Stent
Abbott (NYSE: ABT) today announced at the European Society of Cardiology Congress the widespread availability of its next-generation XIENCE PRIME(TM) Everolimus Eluting Coronary Stent System for the treatment of coronary artery disease. XIENCE PRIME, which received CE Mark (Conformite Europeenne) in June, offers a novel stent design and a delivery system designed for greater flexibility and enhanced deliverability.
Survey Reveals Diabetics Feel the Condition Impacts on Their Mood and Sex LifeAugust 26th, 2009 LONDON - A new research study carried out by The Research Partnership reveals that living with diabetes can have a major effect on people's lives, with just under half (44%) of type 2 patients reporting that the condition has impacted on either their ability or their desire to have sex. The study was conducted online amongst 2,000 patients with type 2 diabetes living in the US, UK and Germany and investigated patients' attitudes, feelings, health status, drug treatment programmes and needs for coping with life with diabetes.
Living Cell Technologies' Diabetes Clinical Trial Authorized by New Zealand GovernmentJune 23rd, 2009 SYDNEY and AUCKLAND, New Zealand -
Living Cell Technologies Limited (ASX: LCT; OTCQX: LVCLY) today announced that the New Zealand Minister of Health, the Honourable Tony Ryall, has authorized LCT's New Zealand Phase I/IIa clinical trial of DIABECELL(R) for insulin dependent diabetes. The authorization confirms the conditions announced on 19 June 2009.
Abbott Receives CE Mark for Company's Next-Generation XIENCE PRIME(TM) Drug Eluting Stent, Advancing Leadership PositionJune 22nd, 2009 ABBOTT PARK, Illinois - Broad Size Matrix of XIENCE PRIME to be Launched in Europe in the Third Quarter
Abbott announced today that it has received CE Mark (Conformite Europeenne) for its next-generation XIENCE PRIME(TM) Everolimus Eluting Coronary Stent System for the treatment of coronary artery disease. The company plans to launch XIENCE PRIME in a broad size matrix with lengths up to 38 mm in Europe in the third quarter.
Abbott's Market-Leading XIENCE V(R) Shows Increasing Clinical Advantages Over TAXUS(R) Express2(TM)/TAXUS(R) Liberte(TM) Between Two and Three YearsMarch 28th, 2009 ORLANDO, Florida - In SPIRIT II Trial, XIENCE V Drug Eluting Stent Demonstrates Clinically
Meaningful Reductions Compared to TAXUS in Key Safety Endpoints, Including an
88 Percent Reduction in the Risk of Cardiac Death at Three Years
Long-term data presented today from Abbott's (NYSE: ABT) SPIRIT II
clinical trial demonstrated that the clinical advantages of the XIENCE V(R)
Everolimus Eluting Coronary Stent System continued to increase between two
and three years compared to the TAXUS(R) Express2(TM) Paclitaxel-Eluting
Coronary Stent System / TAXUS(R) Liberte(TM) Paclitaxel-Eluting Coronary
Stent System (TAXUS). Both TAXUS Express2 (73 percent of lesions) and TAXUS
Liberte (27 percent of lesions) were used as controls in the SPIRIT II trial.
Abbott Advances Its Revolutionary Fully Bioabsorbable Drug Eluting Stent With Initiation of Next Phase of Clinical TrialMarch 23rd, 2009 ABBOTT PARK, Illinois - Abbott (NYSE: ABT) today announced the initiation of the next phase of
the ABSORB clinical trial to evaluate the safety and performance of the
company's fully bioabsorbable drug eluting coronary stent. This second phase
of the ABSORB clinical trial will enroll approximately 80 patients at 10
centers in Europe, Australia and New Zealand, and will incorporate device
enhancements designed to improve deliverability and vessel support.
The Lancet Publishes Two-Year Results of Abbott's Fully Bioabsorbable Drug Eluting StentMarch 11th, 2009 ABBOTT PARK, Illinois - Data Demonstrate Bioabsorbable Stent Is Absorbed Within Two Years,
Leaving Behind Blood Vessels that Appear to Move and Function Similar to
Untreated Vessels
A comprehensive analysis published today in The Lancet, one of the
world's leading medical journals, from the ABSORB clinical trial demonstrated
that Abbott's bioabsorbable drug eluting stent, currently in development,
successfully treated coronary artery disease and was absorbed into the walls
of treated arteries within two years. The two-year data also demonstrated
that after the bioabsorbable device was absorbed, the treated blood vessels
appeared to move and function similar to unstented arteries.
Related News
Iron-binding drug may heal diabetes-related stubborn woundsJuly 28th, 2009 WASHINGTON - A drug used to remove iron from the body has the potential to fight the problem of diabetes-related poor wound healing, according to researchers from Stanford University School of Medicine and the Albert Einstein College of Medicine. Poor wound healing is diabetes' cruellest complications, which could lead to amputation of patients' toes, feet, and even legs.
Chronic diseases linked to higher levels of depressionJanuary 15th, 2009 WASHINGTON - People with chronic obstructive pulmonary disease (COPD) are nearly twice as likely to be depressed as diabetics. Dutch researchers compared the health characteristics of 999 patients with COPD, 978 patients with diabetes, and 2,494 healthy control subjects.
Study: Half of drug addicts quit after 6 months of treatment, but long-term care neededOctober 1st, 2009 Half of addicts quit after 6 months of treatmentLONDON — About half of heroin and crack cocaine addicts in England's treatment programs quit the drugs after six months, a new study says. Experts warned, however, that the danger of relapse means permanently kicking the habit probably requires ongoing care.
Synthetic hormone treatment reduces swollen liversAugust 18th, 2009 LONDON - A six-month treatment with a synthetic gastro-intestinal hormone, Lanreotide, significantly decreased swollen cystic livers, compared to a 'wait and see' policy, says a new research. At least five percent of the population have one or two cysts in the liver.
Fast acting erectile disorder drug goes on trial againFebruary 15th, 2009 WASHINGTON - A new fast-acting oral drug for erectile dysfunction (ED) is ready for a crucial trial phase. It's going to be a multicentre, randomised, double-blind, placebo-controlled trial that will evaluate the safety and efficacy of Avanafil in the treatment of ED in men with type-1 or type-2 diabetes.
Vitamin D2 effectively treats vitamin D deficiencyOctober 27th, 2009 WASHINGTON - A new study by researchers at Boston University School of Medicine researchers has shown that 50,000 International Units (IU) of vitamin D2, given weekly for eight weeks, effectively treats vitamin D deficiency. Vitamin D2 is a mainstay for the prevention and treatment of vitamin D deficiency in children and adults.
Weight loss can cure obstructive sleep apneaFebruary 8th, 2009 LONDON - Losing weight could be the most effective way of reducing obstructive sleep apnea or OSA symptoms and associated disorders, says a new study. Weight loss may not be a new miracle pill or a fancy high-tech treatment, but it is an exciting therapy for sufferers of OSA both because of its short- and long-term effectiveness and for its relatively modest price tag.
Scientists identify genes that determine right warfarin doseMarch 21st, 2009 WASHINGTON - Researchers at Uppsala University, together with colleagues at Karolinska Institute and Sanger Institute, have identified three genes that would help determine the optimal dose of blood-thinning drug warfarin. The team led by Mia Wadelius have come across three genes VKORC1, CYP2C9, and CYP4F2 that would help determine adequate warfarin dosage.
An Indian diabetic cure for Hollywood star Halle BerryApril 18th, 2009 NEW DELHI - With an Oscar statuette under her belt, Hollywood is at Halle Berry's feet. However, life has never been a bed of roses for this brilliant actress, as she has had to battle one of the world's most common illnesses - diabetes.
Eight killed in Turkey hospital fireMay 26th, 2009 ANKARA - Eight people were killed when a major fire broke out in a hospital's intensive care unit in western Turkey, authorities said Tuesday. The dead were patients being treated in the intensive care unit of the Sevket Yilmaz hospital in Bursa, provincial Governor Sahabettin Harputlu was quoted as saying by the semi-official Anatolia news agency.
